Randolph Co Inc grew its holdings in Johnson & Johnson (NYSE:JNJ) by 1.6% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 153,851 shares of the company’s stock after purchasing an additional 2,460 shares during the quarter. Johnson & Johnson comprises about 3.4% of Randolph Co Inc’s investment portfolio, making the stock its 14th largest position. Randolph Co Inc’s holdings in Johnson & Johnson were worth $18,668,000 at the end of the most recent quarter.
A number of other institutional investors have also bought and sold shares of the business. BlackRock Inc. boosted its stake in Johnson & Johnson by 4.7% in the first quarter. BlackRock Inc. now owns 175,389,024 shares of the company’s stock worth $22,476,102,000 after purchasing an additional 7,853,141 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its stake in Johnson & Johnson by 2.0% in the first quarter. Massachusetts Financial Services Co. MA now owns 29,761,934 shares of the company’s stock worth $3,813,993,000 after purchasing an additional 590,069 shares in the last quarter. Fisher Asset Management LLC boosted its stake in Johnson & Johnson by 3.8% in the second quarter. Fisher Asset Management LLC now owns 13,118,604 shares of the company’s stock worth $1,591,811,000 after purchasing an additional 478,982 shares in the last quarter. Boston Partners boosted its stake in Johnson & Johnson by 68.7% in the first quarter. Boston Partners now owns 12,783,909 shares of the company’s stock worth $1,638,258,000 after purchasing an additional 5,207,124 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. boosted its stake in Johnson & Johnson by 4.7% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 8,590,694 shares of the company’s stock worth $1,100,897,000 after purchasing an additional 383,040 shares in the last quarter. 66.67% of the stock is currently owned by institutional investors.
A number of equities analysts have commented on the company. Wells Fargo & Co reissued an “outperform” rating and issued a $160.00 price objective on shares of Johnson & Johnson in a research note on Friday, September 14th. Jefferies Financial Group set a $145.00 price objective on Johnson & Johnson and gave the stock a “buy” rating in a research note on Sunday, July 15th. HC Wainwright reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Wednesday. Credit Suisse Group set a $149.00 price target on Johnson & Johnson and gave the company a “buy” rating in a research note on Sunday, October 14th. Finally, ValuEngine raised Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Saturday, July 28th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $141.54.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 16th. The company reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.03 by $0.02. Johnson & Johnson had a return on equity of 34.97% and a net margin of 1.89%. The business had revenue of $20.35 billion for the quarter, compared to analyst estimates of $20.05 billion. During the same quarter in the prior year, the firm posted $1.90 earnings per share. The firm’s revenue for the quarter was up 3.6% compared to the same quarter last year. Research analysts anticipate that Johnson & Johnson will post 8.16 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 11th. Stockholders of record on Tuesday, November 27th will be paid a dividend of $0.90 per share. This represents a $3.60 annualized dividend and a dividend yield of 2.59%. The ex-dividend date is Monday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 49.32%.
In related news, COO Michael E. Sneed sold 29,000 shares of the company’s stock in a transaction dated Monday, August 27th. The stock was sold at an average price of $134.80, for a total value of $3,909,200.00. Following the completion of the sale, the chief operating officer now owns 59,124 shares in the company, valued at $7,969,915.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Ronald A. Kapusta sold 7,899 shares of the company’s stock in a transaction dated Friday, September 7th. The shares were sold at an average price of $137.18, for a total value of $1,083,584.82. Following the completion of the sale, the chief accounting officer now owns 25,725 shares of the company’s stock, valued at approximately $3,528,955.50. The disclosure for this sale can be found here. Corporate insiders own 0.22% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.